$AGEN

AGENUS INC

Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. Its primary business is immuno-oncology, with botensilimab and balstilimab as its lead clinical program, studied alone and in combination. The company also has earlier-stage antibody programs and discovery platforms for identifying targets, generating antibodies and selecting candidates. Through its subsidiary SaponiQx, Agenus develops saponin-based vaccine adjuvants, including QS-21 STIMULON and cultured plant cell-derived cpcQS-21. It also holds an equity investment in MiNK Therapeutics. Agenus uses internal research, translational, clinical and regulatory capabilities, along with collaborations, to advance product candidates. It receives payments under licensing and collaboration agreements, including milestones and royalties, and recognizes revenue from BOT and BAL supplied through authorized access programs. SaponiQx develops and manufactures adjuvants. Agenus is headquartered in Lexington, Massachusetts.

No enriched coverage for $AGEN in the last 7 days.

No SEC Form 4 filings for $AGEN in the last 30 days.

See all $AGEN insider activity →

Agenus Inc. (AGEN) Reports 51% Survived 18 Months on BOT+BAL

Agenus Inc. reported that 51% of 123 patients with a specific type of colorectal cancer survived at least 18 months on its BOT+BAL treatment, with an estimated 59% of those alive at three years. This is a post-hoc analysis of prior Phase 1b results, not a new trial.

Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones

Agenus plans to begin a Phase 3 trial for colon cancer treatment, with enrollment starting soon. The trial, involving 850 patients, will compare the company's treatment with standard care. Additional funding of up to $255 million is contingent on trial milestones, with enrollment expected to complete by late 2028 and results by 2030.

AGEN sentiment & insider activity

Recent AGEN coverage spans financial news, earnings and technology.

What's driving AGEN

AlphAI scores every news story that mentions AGEN with an AI model for sentiment and relevance, and aggregates insider trades from AGENUS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AGEN

Score
$AGENMedAI 8/10Earnings

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme

$AGENMedAI 8/10

Agenus advances Phase 3 colon cancer trial, posts Q3 profit

Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.

Related tickers